Derivatives and Quantitative Strategist

Gaudenz Schneider

Equity Bottom-Up

Fisher & Paykel Healthcare Cor / Equity Bottom-Up

<ul>
<li>
Context: The <a href="https://www.smartkarma.com/entities/fisher-paykel-healthcare-cor" target="_blank" data-smartkarma-citation="entities:24208:1" rel="noopener">Fisher &amp; Paykel Health (FPH AU)</a> vs. <a href="https://www.smartkarma.com/entities/resmed-inc-cdi" target="_blank" data-smartkarma-citation="entities:22653:1" rel="noopener">ResMed Inc (RMD AU)</a> price-ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.</li>
<li>
Highlights: Going long Fisher &amp; Paykel Health (FPH AU) and short ResMed Inc (RMD AU) targets a 7% return. However, ResMed is more attractively valued on PEG ratio basis.</li>
<li>
Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.</li>
</ul>



Context: The Fisher &amp; Paykel Health (FPH AU) vs. ResMed Inc (RMD AU) price-ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.

Highlights: Going long Fisher &amp; Paykel Health (FPH AU) and short ResMed Inc (RMD AU) targets a 7% return. However, ResMed is more attractively valued on PEG ratio basis.

Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.


Long F&P Health (FPH AU) Vs. Short ResMed (RMD AU): Pair Trade with 7% Upside Potential

New Zealand Professional Investment Services Firm, Forsyth Barr

Forsyth Barr

New Zealand Professional Investment Services Firm

We are proud to be a New Zealand owned firm, with 21 offices throughout the country and over 300 employees. We assist personal, institutional and corporate clients providing a full range of investment services.

Forsyth Barr is a foundation New Zealand Exchange firm (NZX) and accredited market participant. We have been confirmed by the Financial Markets Authority as a Qualifying Financial Entity (QFE).

Research is the cornerstone of our advice. We have one of New Zealand's leading teams of analysts. Our global affiliations ensure comprehensive research coverage of all major investment markets.

Fisher & Paykel Healthcare Corp / Equity Bottom-Up

<ul><li>F&amp;P Healthcare’s (FPH) ASM update highlighted a positive start to FY26.</li><li>Despite lapping a strong 1H25 period, FPH is guiding to revenue and NPAT growth of +13% and +31% in constant currency (CC) terms.</li><li>FPH was understandably reluctant to provide additional colour on the outlook for FY26, aside from reaffirming its guidance.</li></ul>

F&amp;P Healthcare’s (FPH) ASM update highlighted a positive start to FY26.Despite lapping a strong 1H25 period, FPH is guiding to revenue and NPAT growth of +13% and +31% in constant currency (CC) terms.FPH was understandably reluctant to provide additional colour on the outlook for FY26, aside from reaffirming its guidance.

<ul>
<li>
Context: This Insight follows up on previously highlighted relative value opportunities, using a statistical methodology based on mean-reversion to identify opportunities in paired securities.</li>
<li>
Highlight: Currently six pair trade opportunities across three markets and three sectors persist.</li>
<li>
Why read: Statistical analysis offers a unique perspective on relative value. Gain insights into actionable statistical pair trade opportunities and monitor performance of previously highlighted pairs.</li>
</ul>



Context: This Insight follows up on previously highlighted relative value opportunities, using a statistical methodology based on mean-reversion to identify opportunities in paired securities.

Highlight: Currently six pair trade opportunities across three markets and three sectors persist.

Why read: Statistical analysis offers a unique perspective on relative value. Gain insights into actionable statistical pair trade opportunities and monitor performance of previously highlighted pairs.


Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (04 Aug)

<ul><li>F&amp;P Healthcare (FPH) held a thorough and confident investor day in Melbourne.</li><li>The focus was exclusively on ‘changing clinical practice’, with Australia a key early adopter market.</li><li>No new targets or trading updates were provided (as expected).</li></ul>

F&amp;P Healthcare (FPH) held a thorough and confident investor day in Melbourne.The focus was exclusively on ‘changing clinical practice’, with Australia a key early adopter market.No new targets or trading updates were provided (as expected).

F&P Healthcare - 2025 Investor Day—Repeat Flow

<ul>
<li>
Context: The <a href="https://www.smartkarma.com/entities/fisher-paykel-healthcare-cor" target="_blank" data-smartkarma-citation="entities:24208:1" rel="noopener">Fisher &amp; Paykel Healthcare (FPH AU)</a> vs. <a href="https://www.smartkarma.com/entities/resmed-inc-cdi" target="_blank" data-smartkarma-citation="entities:22653:1" rel="noopener">ResMed (RMD AU)</a> Price-Ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.</li>
<li>
Highlights: The long position is supported by higher growth aligning well with the statistical analysis. The trade faces some event risk due to an upcoming earnings announcement.</li>
<li>
Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.</li>
</ul>



Context: The Fisher &amp; Paykel Healthcare (FPH AU) vs. ResMed (RMD AU) Price-Ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.

Highlights: The long position is supported by higher growth aligning well with the statistical analysis. The trade faces some event risk due to an upcoming earnings announcement.

Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.


Fisher & Paykel Healthcare (FPH AU) Vs. ResMed (RMD AU): Dislocation in Healthcare

New Zealand

Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets heated humidification products and systems for use in respiratory care and the treatment of sleep apnea.  The Company also offers patient warming and neonatal care products, including warming products and infant resuscitators.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Fisher & Paykel Healthcare Cor (FPH AU)

Long F&P Health (FPH AU) Vs. Short ResMed (RMD AU): Pair Trade with 7% Upside Potential

The price-ratio between Fisher & Paykel Health and ResMed has diverged by 2 standard deviations, offering a potential relative value opportunity...

Gaudenz Schneider

F&P Healthcare 2025 ASM—Well On Track

F&P Healthcare’s (FPH) ASM update highlighted a positive start to FY26.Despite lapping a strong 1H25 period, FPH is guiding to revenue and NPAT...

Forsyth Barr

Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (04 Aug)

Statistical methodology identifies six pair trade opportunities across three markets and three sectors, offering unique insights into relative value.

Gaudenz Schneider

F&P Healthcare - 2025 Investor Day—Repeat Flow

F&P Healthcare (FPH) held a thorough and confident investor day in Melbourne.The focus was exclusively on ‘changing clinical practice’, with...

Forsyth Barr

Fisher & Paykel Healthcare (FPH AU) Vs. ResMed (RMD AU): Dislocation in Healthcare

FPH AU vs. RMD AU price-ratio deviates from average, offering potential value opportunity for quantitative traders with risk management protocols.

Gaudenz Schneider

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Long F&P Health (FPH AU) Vs. Short ResMed (RMD AU): Pair Trade with 7% Upside Potential

The price-ratio between Fisher & Paykel Health and ResMed has diverged by 2 standard deviations, offering a potential relative value opportunity...

Gaudenz Schneider

F&P Healthcare 2025 ASM—Well On Track

F&P Healthcare’s (FPH) ASM update highlighted a positive start to FY26.Despite lapping a strong 1H25 period, FPH is guiding to revenue and NPAT...

Forsyth Barr

Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (04 Aug)

​Statistical methodology identifies six pair trade opportunities across three markets and three sectors, offering unique insights into relative value.

Gaudenz Schneider

F&P Healthcare - 2025 Investor Day—Repeat Flow

F&P Healthcare (FPH) held a thorough and confident investor day in Melbourne.The focus was exclusively on ‘changing clinical practice’, with...

Forsyth Barr

Fisher & Paykel Healthcare (FPH AU) Vs. ResMed (RMD AU): Dislocation in Healthcare

​FPH AU vs. RMD AU price-ratio deviates from average, offering potential value opportunity for quantitative traders with risk management protocols.

Gaudenz Schneider

Statistical methodology identifies six pair trade opportunities across three markets and three sectors, offering unique insights into relative value.

FPH AU vs. RMD AU price-ratio deviates from average, offering potential value opportunity for quantitative traders with risk management protocols.